Exploring the role of specific genes in cancer treatment
Official title: Genomics Core
Funded at Coriell Institute for Medical Research · NIH-10886776 · Data updated 2026-11-12
This study is looking at how specific genes, like CDK4 and CDK9, can be used to improve cancer treatments, and it’s for patients who want to explore new ways to make their current therapies work better.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Coriell Institute for Medical Research NIH-funded |
| Lab location | 1 site (Camden, United States) |
| Project start | August 16, 2021 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $238,562 |
| NIH project number | 5P50CA254897-04 |
| Project ID | NIH-10886776 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation are patients with cancers that may be influenced by CDK4 and CDK9, particularly those who have not responded to standard treatments.
✕Less likely to help
Patients with cancers unrelated to CDK4 or CDK9, or those who have already exhausted all treatment options, may not benefit from this research.
What this research studies
This research focuses on the Genomics, Epigenomics, and Bioinformatics Core, which supports projects aimed at understanding how certain genes, particularly CDK4 and CDK9, can be targeted for cancer treatment. It involves designing and executing genomic experiments, analyzing data related to gene expression and chromatin accessibility in tumor and immune cells, and conducting clinical trials that combine epigenetic therapies with immunotherapy. Patients may benefit from innovative treatments that enhance the effectiveness of existing cancer therapies through a better understanding of genetic factors. The research aims to provide insights into how these genes influence cancer progression and treatment response.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments by combining epigenetic therapies with immunotherapy.
How similar studies have gone: Previous research has shown promising results in targeting CDK inhibitors in cancer treatment, indicating that this approach has potential for success.
Where this research is happening
-
Coriell Institute for Medical Research
Camden, United States Active
Researchers
- Principal investigator: Jelinek, Jaroslav — Coriell Institute for Medical Research
- Study coordinator: Jelinek, Jaroslav
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.